GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Paliperidone

Local RX List renal extractBase record retrieved 2026-09-05See the evidence for this drug2 sources available - open source summaries, references and comparisons
READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Rxlist source

GlobalRPh RX List - INVEGA tablets

Product / population
Adult oral paliperidone extended-release tablets; not a long-acting injection.
Renal measure
CrCl in mL/min.

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Independently opened product page after the directory-link tool failed; exact I-index href was not verified.

Renal dosing, restrictions and evidence limits

At CrCl 50 to under 80 mL/min, start 3 mg once daily; the maximum is 6 mg daily after response/tolerability assessment. At CrCl 10 to under 50, start 1.5 mg once daily, with a maximum of 3 mg daily after reassessment. Use below 10 is not recommended because it was not studied. Swallow ER tablets intact. These oral instructions must not be transferred to long-acting injectable paliperidone.

Source revision: February 2017 | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/invega-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - INVEGA tablets

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Adult oral paliperidone extended-release tablets; not a long-acting injection.

Renal method: CrCl in mL/min.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGlobalRPh RX List - INVEGA tablets
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

Oral extended-release tablets and the monthly SUSTENNA injection are separate product sections. No regimen is inferred for 3- or 6-month injections.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/paliperidone/

Oral extended-release tablets

Adult schizophrenia or schizoaffective disorder: initially 6 mg/day; range 3-12 mg/day; maximum 12 mg/day. Adolescent schizophrenia: start 3 mg/day. Weight below 51 kg: range 3-6 mg/day, maximum 6; weight at least 51 kg: range 3-12, maximum 12.

GRPH-paliperidone-01 · Source section: Oral extended-release tabletsRenal section finder

Monthly injection - INVEGA SUSTENNA only

IM only. Establish tolerability with oral paliperidone or oral risperidone when naive to oral paliperidone or oral/injectable risperidone. Initiate 234 mg deltoid on day 1, then 156 mg deltoid 1 week later. Recommended monthly maintenance 117 mg, with available alternatives 39, 78, 156 or 234 mg depending on response; maintenance may be deltoid or gluteal.

Deltoid needle: weight at least 90 kg, 1.5-inch 22G; below 90 kg, 1-inch 23G. Gluteal: 1.5-inch 22G at any weight. The source refers missed initiation/maintenance doses to the complete prescribing information and does not provide a missed-dose algorithm locally.

GRPH-paliperidone-02 · Source section: Monthly injection - INVEGA SUSTENNA onlyRenal section finder

Renal dosing - oral tablets

CrCl 50 to under 80 mL/min: start 3 mg daily, maximum 6 mg daily according to response/tolerability.

CrCl 10 to under 50: start 1.5 mg daily; after reassessment, maximum 3 mg daily.

Below 10: not studied; not recommended.

GRPH-paliperidone-03 · Source section: Renal dosing - oral tabletsRenal section finder

Renal dosing - monthly SUSTENNA injection

CrCl 50 to under 80: 156 mg deltoid day 1, then 117 mg deltoid 1 week later, followed by 78 mg monthly deltoid/gluteal in the source regimen.

Below 50: not recommended.

GRPH-paliperidone-04 · Source section: Renal dosing - monthly SUSTENNA injectionRenal section finder

Hemodialysis

Oral tablets are not recommended below CrCl 10; monthly SUSTENNA is not recommended below 50.

GRPH-paliperidone-05 · Source section: HemodialysisRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - INVEGA tablets

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Adult oral paliperidone extended-release tablets; not a long-acting injection.

Renal method: CrCl in mL/min.
Source date: February 2017
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

At CrCl 50 to under 80 mL/min, start 3 mg once daily; the maximum is 6 mg daily after response/tolerability assessment. At CrCl 10 to under 50, start 1.5 mg once daily, with a maximum of 3 mg daily after reassessment. Use below 10 is not recommended because it was not studied. Swallow ER tablets intact. These oral instructions must not be transferred to long-acting injectable paliperidone.

RDM43-rxlist-paliperidone-6c926a5b53-C1 · Source locator: Selected Dosage / Renal Impairment / Warnings sections; see source-specific qualifications in this summary.

Source-specific limits

Independently opened product page after the directory-link tool failed; exact I-index href was not verified.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/invega-drug/
Retrieved
2026-09-07
Renal-function method
CrCl in mL/min.
Source date/version
February 2017
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
aa6b65d3ed6360196e8f5ec1da4689f862147d4c515984fbc3615dade5165626

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/paliperidone/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
6327392588f51cc21df1e161ae21f93cfb8aeaac7dd280555224ff574164c09a
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report